Sounds like good advice...so I did a little research on AMRN and found that they received approval in other countries outside of the U.S. before getting FDA approval to market within the U.S.
This gave the generic companies in the U.S. an upper hand to create a substitute generic and sell it under another name. This has led to a very messy patent court battle.
I don't think AVXL has to worry about that scenario because they are getting A2-73 approved in the U.S. first for Rett...which should protect them from any patent infringement from the generics and BPs.